On January 5th, Yifan Pharmaceutical...The company announced that its wholly-owned subsidiary, Yifan Pharmaceutical, has signed exclusive agreements with Shangde Pharmaceutical and Tianjin Shangde respectively. Under these agreements, Shangde Pharmaceutical grants Yifan Pharmaceutical an irrevocable and exclusive right to license its independently developed product, dimethylamino micaceous lactone fumarate monohydrate, within the designated cooperation area. Yifan Pharmaceutical is authorized to use the licensed intellectual property rights within the cooperation area.The company will develop, manufacture, and commercialize the target product, and simultaneously grant exclusive priority negotiation rights for the production and commercialization of the target product for other indications within the cooperation area. In addition, Yifan Pharmaceutical will pay Shangde Pharmaceutical a down payment of RMB 100 million, a cornerstone investment of RMB 100 million or a milestone payment of RMB 50 million (choose one), tiered net sales revenue sharing, and a share of sublicense revenue outside of China (if any).

The announcement indicates that ACT001 is a Class 1 innovative drug with a novel mechanism.Its active ingredient is dimethylaminonitrobenzyl fumarate monohydrate, which exerts its anti-tumor effect by inhibiting the NF-κB and STAT3 signaling pathways. This drug has undergone multiple clinical trials in China, the United States, and Australia. In January 2025, it received "Breakthrough Therapy" designation from the National Medical Products Administration (NMPA) for its indication of small cell lung cancer brain metastases. It is currently in the Phase III clinical trial enrollment phase (52 patients have been enrolled). The company stated that this collaboration marks a significant step forward in Yifan Pharmaceutical 's innovative strategy in the field of oncology treatment.

https://finance.eastmoney.com/a/202601053609124029.html